Brief: Rilvegostomig, Astrazeneca's Bi-Specific Antibody Derived From Compugen's Com902, Expected To Progress Into Phase 3

Compugen

14/02/2023 12:09

Feb 14 (Reuters) - Compugen Ltd  CGEN.TA :
    * RILVEGOSTOMIG, ASTRAZENECA'S BI-SPECIFIC ANTIBODY DERIVED
FROM
COMPUGEN'S COM902, EXPECTED TO PROGRESS INTO PHASE 3
    * COMPUGEN LTD -  PHASE 3 STUDY WITH RILVEGOSTOMIG IS
EXPECTED TO
START IN 2023

Source text for Eikon:  ID:nPn9RWB7Qa 
Further company coverage:  CGEN.TA 
 ((Reuters.Briefs@thomsonreuters.com;;))